Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Low expression of BAZ2B may promote breast cancer progression by reshaping tumour metabolism. Read on to learn more.

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Next-Generation ...